Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin
© 2020 Elsevier B.V. Programmed death ligand 1 (PD-L1) is overexpressed in some metastatic breast cancer subtypes, specifically triple-negative breast cancer (TNBC). This feature can assist in the eradication of anti-tumor immunity, thereby enhancing the survival of the tumor. This study aims to exp...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Journal |
Published: |
2020
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85087655505&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/70646 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
id |
th-cmuir.6653943832-70646 |
---|---|
record_format |
dspace |
spelling |
th-cmuir.6653943832-706462020-10-14T08:47:03Z Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin Prachya Kongtawelert Benjawan Wudtiwai Thuzar Hla Shwe Peraphan Pothacharoen Thanyaluck Phitak Immunology and Microbiology Medicine Pharmacology, Toxicology and Pharmaceutics © 2020 Elsevier B.V. Programmed death ligand 1 (PD-L1) is overexpressed in some metastatic breast cancer subtypes, specifically triple-negative breast cancer (TNBC). This feature can assist in the eradication of anti-tumor immunity, thereby enhancing the survival of the tumor. This study aims to explore how sesamin affects PD-L1 expression in breast cancer cells and its related molecular mechanisms. We found high levels of expression of PD-L1 in both mRNA and protein levels in the TNBC cell line, MDA-MB231, but not in the luminal type-breast cancer cell line, MCF-7. We then demonstrated the tumor suppressive effect of sesamin, which induced the inhibition of cell proliferation in MDA-MB231 cells. Additionally, sesamin triggered PD-L1 downregulation (both mRNA and protein) through the inhibition of AKT, NF-κB and JAK/Stat signaling in MDA-MB231 cells. Moreover, the migration ability of MDA-MB231 cells was effectively diminished by sesamin via inhibition of the activation of MMP-9 and MMP-2. In summary, this study demonstrated that sesamin suppresses MDA-MB231 breast cancer cells’ proliferation and migration; and decreases the expression of PD-L1 via the downregulation of AKT, NF-κB, and JAK/Stat signaling. Therefore, sesamin may be an effective alternative and novel therapeutic option for immunotherapy in breast cancer cells with high PD-L1 expression. 2020-10-14T08:37:01Z 2020-10-14T08:37:01Z 2020-09-01 Journal 18781705 15675769 2-s2.0-85087655505 10.1016/j.intimp.2020.106759 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85087655505&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/70646 |
institution |
Chiang Mai University |
building |
Chiang Mai University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Chiang Mai University Library |
collection |
CMU Intellectual Repository |
topic |
Immunology and Microbiology Medicine Pharmacology, Toxicology and Pharmaceutics |
spellingShingle |
Immunology and Microbiology Medicine Pharmacology, Toxicology and Pharmaceutics Prachya Kongtawelert Benjawan Wudtiwai Thuzar Hla Shwe Peraphan Pothacharoen Thanyaluck Phitak Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin |
description |
© 2020 Elsevier B.V. Programmed death ligand 1 (PD-L1) is overexpressed in some metastatic breast cancer subtypes, specifically triple-negative breast cancer (TNBC). This feature can assist in the eradication of anti-tumor immunity, thereby enhancing the survival of the tumor. This study aims to explore how sesamin affects PD-L1 expression in breast cancer cells and its related molecular mechanisms. We found high levels of expression of PD-L1 in both mRNA and protein levels in the TNBC cell line, MDA-MB231, but not in the luminal type-breast cancer cell line, MCF-7. We then demonstrated the tumor suppressive effect of sesamin, which induced the inhibition of cell proliferation in MDA-MB231 cells. Additionally, sesamin triggered PD-L1 downregulation (both mRNA and protein) through the inhibition of AKT, NF-κB and JAK/Stat signaling in MDA-MB231 cells. Moreover, the migration ability of MDA-MB231 cells was effectively diminished by sesamin via inhibition of the activation of MMP-9 and MMP-2. In summary, this study demonstrated that sesamin suppresses MDA-MB231 breast cancer cells’ proliferation and migration; and decreases the expression of PD-L1 via the downregulation of AKT, NF-κB, and JAK/Stat signaling. Therefore, sesamin may be an effective alternative and novel therapeutic option for immunotherapy in breast cancer cells with high PD-L1 expression. |
format |
Journal |
author |
Prachya Kongtawelert Benjawan Wudtiwai Thuzar Hla Shwe Peraphan Pothacharoen Thanyaluck Phitak |
author_facet |
Prachya Kongtawelert Benjawan Wudtiwai Thuzar Hla Shwe Peraphan Pothacharoen Thanyaluck Phitak |
author_sort |
Prachya Kongtawelert |
title |
Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin |
title_short |
Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin |
title_full |
Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin |
title_fullStr |
Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin |
title_full_unstemmed |
Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin |
title_sort |
inhibition of programmed death ligand 1 (pd-l1) expression in breast cancer cells by sesamin |
publishDate |
2020 |
url |
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85087655505&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/70646 |
_version_ |
1681752940616876032 |